Antibody Conjugation

Home / Custom Synthesis / Bioconjugation / Antibody Conjugation

Antibody Conjugation

BOC Sciences has unique R & D expertise to provide you with the highest quality antibody conjugation services in the industry. We can provide customers with custom antibody conjugation services of different sizes and reasonable prices in a short period. At the same time, we provide a comprehensive and complete analysis report of antibody conjugates. BOC Sciences also provides world-class expertise in methods that can handle powerful and toxic payloads. In the process of development and production, each antibody conjugate is strictly monitored according to our strict quality assurance and quality control standards.

Antibody conjugates play an important role in biological agents targeted therapeutic studies, and immunoassay or detection applications. The custom antibody bioconjugation services can be achieved by using monoclonal antibody or polyclonal antibody through chemical conjugation with other biomolecules. One method is the conjugation of antibodies and their fragments with biologically active molecules, including nucleic acids, oligonucleotides and their analogs, peptides, proteins. Another way is the conjugation of antibodies and their fragments with any molecular group that adds valuable properties such as radionuclides, drugs, toxins, enzymes, metal chelates, fluorophores, haptens, and others.

Below is a list of our Antibody Conjugates Services (include but not limited to the following):

Antibody-enzyme conjugation is designed as a new approach for disease therapy, especially for cancer therapy. Conjugation of enzymes to antibodies is the formation of a stable, covalent linkage between an antigen‐specific monoclonal or polyclonal antibody and enzyme, such as horseradish peroxidase (HRPO), urease, or alkaline phosphatas.

More than a century ago, Paul Ehrlich proposed the concept of “antibody-drug conjugates (ADCs)” as one of the targeted therapies. Now ADCs are being regarded as very important and promising antitumor agents. There are four conjugates that have been approved by regulatory agencies for treating cancer patients. The typical method is the conjugation of cytotoxins or chemotherapeutic drugs (such as cysteine, glutamine, unnatural amino acids, short peptide tags, and glycans) with specifically defined sites in antibody molecules.

A large number of polymers have the ability to conjugate with antibodies. Antibody conjugation to polymers directed against tumor associated antigens is a new research area for scientists. The drug delivery systems, composed of polymers and their conjugates with antibodies, fragments of antibodies or oligopeptides, is suitable as carriers mainly for anticancer or anti-inflammatory agents.

We also provide complete characterization services for antibody conjugates:

  • Advanced Analysis method: HPLC (HIC,SEC,RP), iCIEF,LC-MS.
  • The analysis covers all stages of development and research: drug-to-antibody ratio(DAR), ADC affinity, protein concentration, peptide map analysis, and efficacy testing, etc.
  • In vitro pharmacology: more than 100 common tumor cell lines (including the NCI-60 group) are used in cytotoxicity studies.
  • The scale of production ranges from 1 mg to 10 g, which can be used for in vitro and in vivo research.

Why Choose BOC Sciences?

BOC Sciences provides high-quality, low-cost, high-tech products to customers around the world. We has employed a dedicated staff of professional chemists to help you develop the most efficient process for synthesis of antibody conjugations. With diverse state-of-the-art technologies and approaches, clients’ synthetic route can be developed and optimized in the most cost effective way. Each step of product synthesis is subject to BOC Sciences’ stringent quality control.

References

  1. Grüttner, C., Müller, K., Teller, J., Westphal, F., Foreman, A., & Ivkov, R. (2007). Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy. Journal of Magnetism and Magnetic Materials311(1), 181-186.
  2. Orelma, H., Teerinen, T., Johansson, L. S., Holappa, S., & Laine, J. (2012). CMC-modified cellulose biointerface for antibody conjugation. Biomacromolecules13(4), 1051-1058.
Quote Request
Verification code